Skip to main content
SpringerLink
Log in

HIV and AIDS

  • Chapter
Brackenridge’s Medical Selection of Life Risks

  • 66 Accesses

Abstract

At the beginning of the third decade of AIDS, it is evident that the global HIV epidemic is quite different from the limited infectious disease first recognized among a small number of homosexual men in 1981. The epidemic has reached every country and nearly all populations throughout the world. The spreading of the disease has been particularly alarming in developing countries, especially sub-Saharan Africa and southeast Asia, but continues to threaten especially the populations in Eastern Europe, Latin America, and the Caribbean. In the more developed countries, which have also witnessed dramatic increases in HIV/AIDS over the past two decades, marked advances in HIV antiretroviral therapy have resulted in significant changes in the survival rate and quality of life of HIV-infected individuals. Current treatments are effective, allowing HIV-infected individuals to live longer and healthier lives, but at the same time have resulted in complacency and a resurgence in high-risk behavior among some populations.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 279.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Grosskurth H et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet 1995; 346(8974): 530–6.

    Article  CAS  PubMed  Google Scholar 

  2. Pedersen C et al. Clinical course of primary HIV infection: consequences for subsequent course of infection. BMJ 1989; 299(6692): 154–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Tindall B et al. Characterization of the acute clinical illness associated with human immunodeficiency virus infection. Arch Intern Med 1988; 148(4): 945–9.

    Article  CAS  PubMed  Google Scholar 

  4. Clark SJ et al. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med 1991; 324(14): 954–60.

    Article  CAS  PubMed  Google Scholar 

  5. Quinn TC et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342(13): 921–9.

    Article  CAS  PubMed  Google Scholar 

  6. Daar ES et al. Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network. Ann Intern Med 2001; 134(1): 25–9.

    Article  CAS  PubMed  Google Scholar 

  7. de Wolf F et al. Risk of AIDS related complex and AIDS in homosexual men with persistent HIV antigenaemia. Br Med J (Clin Res Ed) 1987; 295(6598): 569–72.

    Article  Google Scholar 

  8. Schacker T et al. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 1996; 125(4): 257–64.

    Article  CAS  PubMed  Google Scholar 

  9. Pantaleo G et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993; 362(6418): 355–8.

    Article  ADS  CAS  PubMed  Google Scholar 

  10. Mellors JW et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272(5265): 1167–70.

    Article  ADS  CAS  PubMed  Google Scholar 

  11. Schacker TW et al. Biological and virologic characteristics of primary HIV infection. Ann Intern Med 1998; 128(8): 613–20.

    Article  CAS  PubMed  Google Scholar 

  12. Giorgi JV et al. Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr 2002; 29(4): 346–55.

    Article  PubMed  Google Scholar 

  13. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recom Rep 1992;41(RR-17): 1–19.

    Google Scholar 

  14. Mellors JW et al. Plasma viral load and CD4+lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126(12): 946–54.

    Article  CAS  PubMed  Google Scholar 

  15. Vlahov D et al. Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4+ cell count. JAMA 1998; 279(1): 35–40.

    Article  CAS  PubMed  Google Scholar 

  16. Ledergerber B et al. Discontinuation of secondary prophylaxis against Pneumocystis carimi pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. N Engl J Med 2001; 344(3): 168–74.

    Article  CAS  PubMed  Google Scholar 

  17. Furrer H et al. Discontinuation of primary prophylaxis in HIV-infected patients at high risk of Pneurnocystis carinii pneumonia: prospective multicentre study. AIDS 2001, 15(4): 501–7.

    Article  CAS  PubMed  Google Scholar 

  18. Beral V et al. Kaposi’s sarcoma among persons with AIDS: a sexually transmitted infection? Lancet 1990; 335(8682): 123–8.

    Article  CAS  PubMed  Google Scholar 

  19. Cote TR et al. Non Hodgkin’s lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group. Int J Cancer 1997; 73(5): 645–50.

    Article  CAS  PubMed  Google Scholar 

  20. Little SJ et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347(6): 385–94.

    Article  CAS  PubMed  Google Scholar 

  21. Palella FJ Jr et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med 2003; 138(8): 620–6.

    Article  PubMed  Google Scholar 

  22. Le M et al. Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen. J Infect Dis 2002; 185(4): 471–80.

    Article  Google Scholar 

  23. Piketty C et al. Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologie responses to a protease inhibitor-containing regimen. J Infect Dis 2001; 183(9): 1328–35.

    Article  CAS  PubMed  Google Scholar 

  24. Alexander CS et al. HIV protease and reverse transcriptase variation and therapy outcome in antiretroviral-naive individuals from a large North American cohort. AIDS 2001; 15(5): 601–7.

    Article  CAS  PubMed  Google Scholar 

  25. Demeter LM et al. Predictors of virologie and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320. Annlntern Med 2001; 135(11): 954–64.

    CAS  Google Scholar 

  26. Friis-Moller N et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349(21): 1993–2003.

    Article  PubMed  Google Scholar 

  27. Jaggy C et al. Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population. Lancet 2003; 362(9387): 877–8.

    Article  PubMed  Google Scholar 

  28. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992; 41 (RR-17): 1–19.

    Google Scholar 

Download references

Authors
  1. Jan von Overbeck
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Annelies S. Zinkernagel
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Swiss Re Life & Health, London, UK

    R. D. C. Brackenridge MD FRCP (Glasg) (Consulting Medical Officer) & Richard S. Croxson MB FRACP (Cardiologist, Chief Medical Officer) (Consulting Medical Officer) &  (Cardiologist, Chief Medical Officer)

  2. Toronto General Hospital, Toronto, Ontario, Canada

    Ross MacKenzie MD, FRCP (C) FACC (Cardiologist) (Cardiologist)

Copyright information

© 2006 Jan Von Overbeck Annelies S. Zinkernagel

About this chapter

Cite this chapter

von Overbeck, J., Zinkernagel, A.S. (2006). HIV and AIDS. In: Brackenridge, R.D.C., Croxson, R.S., MacKenzie, R. (eds) Brackenridge’s Medical Selection of Life Risks. Palgrave Macmillan, London. https://doi.org/10.1007/978-1-349-56632-7_35

Download citation

  • DOI: https://doi.org/10.1007/978-1-349-56632-7_35

  • Publisher Name: Palgrave Macmillan, London

  • Print ISBN: 978-1-349-56634-1

  • Online ISBN: 978-1-349-56632-7

  • eBook Packages: Palgrave History CollectionHistory (R0)

Publish with us

Policies and ethics

Search

Navigation